BSE, NSE Stock Ticker

Tuesday, October 12, 2010

Call Update: Kilitch Drugs

Call Update: Kilitch Drugs recently debuted on NSE also. My call did not go well on this counter so far. But I do not see ANY problems with this script at all. And that is because:

  • It has a healthy balance sheet and is profitable with sufficient reserve money.
  • They export their products to many countries (countries like Algeria, Burundi, Cameroon, Eritrea, Ghana, Iraq, Nigeria, Russia, Senegal, Sri Lanka, Tchad, Niger, Ethiopia, Yemen, Sudan, Tanzania, Uganda to name a few) and they also get repeat orders.
  • By end of this financial year, they plan to expand to 40 countries.
  • They have recently forayed into eye care business, which is growing at an annual rate of 12%.
  • Having achieved USFDA & UKMHRA compliance for their facilities, they can now plan to foray into the regulated markets of USA and Europe.
  • Anti-malaria, NSAIDs, cephalosporin, carbapenems are part of the list of the products they manufacture and these products have defined export markets.
  • They have long term partnerships with famous clients like RANBAXY, SANDOZ, ZYDUS CADILLA, MERCK, GLENMARK, NICHOLAS, UNICHEM to name a few.
  • Towards the end of October 2010, they will be launching their products in Ethiopia.

Hold Kilitch for a few months for it to stabilize and bounce back and reach the target of 148-150. One can average around 110.

 

On Thu, Sep 9, 2010 at 10:29 AM, POWERFULPICKS POWERFULPICKS <powerfulpicks@gmail.com> wrote:

powerfulpicks short term call: Buy Kilitch Drugs (BSE only) on dips around 127 for a short term 1-2 month target of 148 (+13%).

No comments:

Post a Comment